drugset / Trial / NCT01531790
A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the safety, tolerability, clinical efficacy and pharmacokinetics of continuous Endostar intravenous infusion combined with pemetrexed and carboplatin in advanced non small cell lung cancer (NSCLC) patients.
Timeline
- Start
- 2011-09
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Endostar | Protein / enzyme biologic | 7.5 mg/m2 | Intravenous |
| Subject | Endostar | Protein / enzyme biologic | 15 mg/m2 | Intravenous |
| Subject | Endostar | Protein / enzyme biologic | 30 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Background | Centrum | Unknown | — | — |